Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carvedilol in heart failure

D T Kelly1

  • 1Hallstrom Institute of Cardiology, University of Sydney, Australia.

Cardiology
|January 1, 1993
PubMed
Summary

Beta blockers, like carvedilol, improve chronic heart failure symptoms and exercise capacity. This oral treatment, initiated at low doses and gradually increased, enhances left-ventricular ejection fraction by reducing pathological adrenergic drive.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial dysfunction: therapy revisited (brief excerpts) (round table discussion on 18/01/2001 at Mumbai).

Journal of the Indian Medical Association·2001
Same author

Disease burden of cardiovascular disease in the elderly.

Coronary artery disease·1998
Same author

Paul Dudley White International Lecture. Our future society. A global challenge.

Circulation·1997
Same author

Beta-blocker therapy in heart failure: myths or realities.

Journal of cardiac failure·1996
Same author

Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period.

Journal of the American College of Cardiology·1995
Same author

Vascular effects of diuretics in heart failure.

British heart journal·1994

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure is associated with enhanced adrenergic stimulation, leading to decreased myocardial beta-receptor sensitivity.
  • Beta blockers are hypothesized to counteract this pathological adrenergic drive.

Purpose of the Study:

  • To evaluate the efficacy and safety of sustained oral treatment with carvedilol in patients with chronic heart failure.
  • To assess the impact of carvedilol on heart failure symptoms, exercise capacity, and left-ventricular ejection fraction.

Main Methods:

  • Non-placebo-controlled trials involving gradual dose increase of beta blockers over weeks.
  • A multicenter trial designed to evaluate carvedilol's efficacy and safety in heart failure patients.

Main Results:

  • Sustained oral beta-blocker treatment improves symptoms, exercise capacity, and left-ventricular ejection fraction.
  • Carvedilol, a beta-blocker with vasodilatory properties, may further decrease left-ventricular afterload.
  • Recent studies indicate symptomatic improvement with carvedilol in heart failure patients.

Conclusions:

  • Sustained oral beta-blocker therapy is beneficial for chronic heart failure management.
  • Carvedilol shows promise in improving heart failure outcomes due to its combined beta-blocking and vasodilatory effects.

Related Experiment Videos